Agents targeting TP53 mutations include APR‐246, MK‐1775, ALT‐801, and Kevetrin,40 and while these agents are still in early‐stage clinical trials, promising results have been reported in metastatic colon cancer, acute myeloid leukemia, and myelodysplastic syndromes.41, 42. The gene discussed is TP53; the disease is acute myeloid leukemia.